Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PIK3CA | P42336 | 1/20 | 0.51 |
| ▸ | MTOR | P42345 | 1/20 | 0.51 |
| ▸ | GRM5 | P41594 | 7/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.41 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.41 |
| ▸ | AOC3 | Q16853 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24018507 | 0.84 | KMT2A (0.53) | KMT2AALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL31182223 | 0.84 | KMT2A (0.53) | KMT2AALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL18436130 | 0.84 | KMT2A (0.53) | KMT2AALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL15743968 | 0.84 | KMT2A (0.53) | KMT2AALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL10034110 | 0.84 | KMT2A (0.53) | KMT2AALDH1A1CYP1A2CYP3A4CYP2C9 | |
| SCHEMBL20456767 | 0.81 | KMT2A (0.48) | PIK3CAMTORGRM5KMT2AALDH1A1 | |
| SCHEMBL20469115 | 0.80 | CHRNB2 (0.43) | GRM5 | |
| SCHEMBL20468981 | 0.77 | GRM5 (0.39) | GRM5 | |
| SCHEMBL23253135 | 0.77 | PIK3CA (0.54) | PIK3CAMTORGRM5ALDH1A1LMNA | |
| SCHEMBL20469234 | 0.74 | GRM5 (0.42) | GRM5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3909949-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | Gilead Sciences, Inc. (US) | 2021-11-17 | — | — | EP | disclosed |
| EP-3577110-B1 | 8-OXETAN-3-YL-3,8-DIAZABICYCLO[3.2.1]OCTAN-3-YL SUBSTITUTED COMPOUNDS AS HIV INHIBITORS | GILEAD SCIENCES INC (US) | 2021-04-21 | — | — | EP | disclosed |
| WO-2018145021-A1 | ATAZANAVIR (ATV) ANALOGUES FOR TREATING HIV INFECTIONS | GILEAD SCIENCES, INC. (US) | 2018-08-09 | — | — | WO | disclosed |